tiprankstipranks
Trending News
More News >

RAMM Pharma Explores Sale of Italian Subsidiary Canapar

Story Highlights
RAMM Pharma Explores Sale of Italian Subsidiary Canapar

Confident Investing Starts Here:

Ramm Pharma ( (TSE:RAMM) ) has provided an announcement.

RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.

More about Ramm Pharma

RAMM Pharma is a company engaged in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and hemp-based products. It operates a diversified international production and sales platform, with a significant presence in Uruguay where it develops and sells medically registered cannabinoid pharmaceutical products in various Latin American countries. The company also has operations in Europe, particularly in Italy and Poland, and includes subsidiaries like Canapar Corp. and HemPoland.

YTD Price Performance: 0%

Average Trading Volume: 146,334

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$1.79M

See more data about RAMM stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1